Cefepime is more costeffective than ceftriaxone in patients with nursing home-acquired pneumonia not requiring hospitali
- PDF / 136,633 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 75 Downloads / 195 Views
researchers. In their trial,* 69 patients ≥ 60 years of age were randomised to receive IM cefepime 1g or IM ceftriaxone 1g, once daily for up to 10 to 14 days. A switch to oral antibiotics was permitted from day 3 onwards. Clinical success rates were similar in the cefepime and ceftriaxone groups (78% vs 66%). The mean cost per patient was higher in the ceftriaxone group than the cefepime group ($US1128 vs $US466).** Cost-effectiveness ratios indicated that each successfully treated patient would cost $US597 if receiving cefepime and $US1079 if receiving ceftriaxone.
´ * supported by Elan Pharmaceuticals ** Costs were estimated from a provider perspective and included the IM cephalosporin, oral antibiotics and hospitalisations. Paladino JA, et al. Once-daily cefepime versus ceftriaxone for nursing homeacquired pneumonia. Journal of the American Geriatrics Society 55: 651-657, 801077032 No. 5, May 2007
1173-5503/10/0533-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 28 Jul 2007 No. 533
1
Data Loading...
